Join 60,000+ competitive exam aspirants
or with email
Your Cart
SubtotalтВ╣0
TotalтВ╣0
Examoogle тАв User тАв info@examoogle.com тАв EE-2024-8821
Chapter 1 of 12 тАв Page 1 of 248ЁЯФТ Protected PDF тАв Watermarked
Join 60,000+ competitive exam aspirants
SHetA2, recently seen in the news, is primarily being developed for the treatment of which disease?
Dengue
Tuberculosis
Japanese Encephalitis
Cervical cancer caused by HPV
Cervical cancer caused by HPV
SHetA2, a novel small molecule oral therapy, is being developed for the treatment of cervical cancer caused by HPV.
SHetA2 represents a significant advancement in oncology, focusing on preventing the progression of HPV infection into cervical cancer. It is designed to target specific proteins that enable the survival of cancer-causing HPV proteins. The development is a result of a collaborative effort between the Indian Council of Medical Research (ICMR) and international research partners. This therapeutic development aligns with global and national efforts to reduce the burden of cervical cancer through innovative pharmacological interventions.
SHetA2 targets proteins mortalin, hsc70, and Grp78
Developed through collaboration between ICMR-NICPR (India) and Stephenson Cancer Center (USA)
Administered as an oral capsule therapy
Specifically targets HPV-induced cervical dysplasia and cancer progression
D is correct тАФ SHetA2 is a novel oral therapeutic candidate designed to prevent HPV infection from progressing to cervical cancer.
Remember that SHetA2 is an 'oral' therapy; relate this to the broader shift in modern medicine toward non-invasive (oral vs. injectable) treatments for cancer, which is a common theme in recent medical biotechnology MCQs.
Get instant step-by-step AI explanations, full shift Previous Year Papers (SSC GD, RRB, SSC JE), and regional rank analysis on the official Examoogle App.
Free Download тАв 100K+ Aspirants